title: Aspirin in prevention of ovarian cancer: are we at the tipping point?
authors: Affiliations of authors: Bras Drug Development Program, Division of Medical Oncology (DT and AO) and Cancer Clinical Research Unit (TP and AO), Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
authors: Daliah
authors: D
authors: Tsoref
authors: Tony
authors: T
authors: Panzarella
authors: Amit
authors: A
authors: Oza
mesh_terms: D000082:Acetaminophen / Q000008:administration & dosage*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage*; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D006801:Humans; D009375:Neoplasms, Glandular and Epithelial / Q000517:prevention & control*; D010051:Ovarian Neoplasms / Q000517:prevention & control*; D020011:Protective Agents / Q000008:administration & dosage*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D020011:Protective Agents; D000082:Acetaminophen; D001241:Aspirin